V212 Lot 1 + V212 Lot 2 + V212 Lot 3
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster
Trial Timeline
Jul 1, 2014 → Mar 1, 2015
NCT ID
NCT02180295About V212 Lot 1 + V212 Lot 2 + V212 Lot 3
V212 Lot 1 + V212 Lot 2 + V212 Lot 3 is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02180295. Target conditions include Herpes Zoster.
What happened to similar drugs?
8 of 20 similar drugs in Herpes Zoster were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02180295 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Herpes Zoster